RZV offers substantial clinical and economic benefits but has low uptake among adults aged 50 and older compared to other vaccines. By 2020, only 10.8% of adults aged 50 and older had completed both ...

As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...

Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...

Japanese patients with vitiligo experienced lower quality of life and higher levels of anxiety and depression, especially when the disease affected their social life or had relapsed, according to a ...

The Managed Healthcare Executive 2025 State of the Industry survey is a timely snapshot of how payers, providers and pharmacy ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

High consumption of ultra-processed foods elevates the risk of early-onset colorectal cancer, highlighting the need for ...

From 2017 to 2024, newly diagnosed multiple myeloma (MM) patients rapidly received quadruplet therapies over triplets, with ...

Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...